Here's what the filing actually says: the company that helped build the GLP-1 market is already designing its successor, and the successor isn't GLP-1 alone — it's GLP-1 plus a second appetite hormone called amylin.
Strip away the speculation about what comes after today's blockbusters and look at the grant. Novo Nordisk's US12054528B2 covers co-agonists of the GLP-1 and amylin receptors — a single engineered molecule that activates both. The companion publication US20240279299A1 stakes out the same co-agonist territory in more detail.
Why amylin? In plain terms, amylin is another hormone the body uses to say 'enough' after a meal — it slows stomach emptying and dampens appetite through a different pathway than GLP-1. Combine the two and, the theory goes, you get a stronger, more complete satiety signal from one drug.
This is the same multi-receptor logic that has driven the whole field, but with a new partner. Earlier the pairing was GLP-1 with GIP or glucagon. Here it is GLP-1 with amylin — a sign the design space is still expanding, not consolidating.
The crosswalk worth holding: a company's patents are its strategy stated under oath. Novo isn't just renewing claims on what it already sells; the 2024 grant shows it building the next molecule on a different hormone combination. That is a forward bet, written into the patent record before any product launch.
So when you read that the obesity leaders face competition and a future cliff, balance it against this: the same companies are filing the patents that define the next generation. The GLP-1/amylin co-agonist is one concrete, verifiable example of where that next bet points.